News
BDSX
1.280
+6.67%
0.080
Insider Purchase: Director at $BDSX (BDSX) Buys 100,000 Shares
Barchart · 18h ago
Friday 11/22 Insider Buying Report: BDSX, KINS
NASDAQ · 20h ago
Insider Purchase: Director at $BDSX (BDSX) Buys 200,000 Shares
Barchart · 1d ago
Weekly Report: what happened at BDSX last week (1111-1115)?
Weekly Report · 5d ago
Weekly Report: what happened at BDSX last week (1104-1108)?
Weekly Report · 11/11 11:20
Biodesix (BDSX) Receives a Buy from Scotiabank
TipRanks · 11/04 12:47
Biodesix: Strong Growth Prospects Amidst Challenges Lead to Buy Rating
TipRanks · 11/04 12:45
Weekly Report: what happened at BDSX last week (1028-1101)?
Weekly Report · 11/04 11:18
Biodesix Reports Strong Q3 2024 Growth in Diagnostics
TipRanks · 11/02 04:12
Biodesix: Poised for Recovery and Growth Amid Temporary Setbacks
TipRanks · 11/01 20:45
Form 10-Q for Biodesix, Inc. for the quarterly period ended September 30, 2024
Press release · 11/01 20:36
Biodesix Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/01 14:32
Morning Movers: Apple dips, Amazon gains after earnings
TipRanks · 11/01 12:55
Biodesix files to sell 62.2M shares of common stock for holders
TipRanks · 11/01 11:15
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/01 11:15
BIODESIX FILES PROSPECTUS RELATES TO PROPOSED RESALE BY SELLING STOCKHOLDERS OF UP TO 62.2 MLN SHARES OF COMMON STOCK- SEC FILING
Reuters · 11/01 11:14
BIODESIX INC - FILES FOR MIXED SHELF OF $250 MLN- SEC FILING
Reuters · 11/01 11:07
Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M
Seeking Alpha · 11/01 10:09
Biodesix reports Q3 EPS (7c), consensus (7c)
TipRanks · 11/01 10:05
Biodesix Q3 2024 GAAP EPS $(0.07), Inline, Sales $18.151M Miss $18.611M Estimate
Benzinga · 11/01 10:03
More
Webull provides a variety of real-time BDSX stock news. You can receive the latest news about BIODESIX INC through multiple platforms. This information may help you make smarter investment decisions.
About BDSX
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.